uniQure (QURE) Stock Rating Lowered by ValuEngine
uniQure (NASDAQ:QURE) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
QURE has been the topic of several other research reports. Zacks Investment Research raised uniQure from a “sell” rating to a “hold” rating and set a $9.25 price objective on the stock in a research report on Wednesday, August 9th. Leerink Swann upped their price objective on uniQure from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Evercore ISI began coverage on uniQure in a research note on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price objective for the company. Oppenheimer reiterated a “hold” rating on shares of uniQure in a research note on Friday, November 24th. Finally, HC Wainwright began coverage on uniQure in a research note on Friday. They issued a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $18.75.
uniQure (QURE) traded up $0.42 during midday trading on Friday, reaching $15.56. The company had a trading volume of 536,307 shares, compared to its average volume of 395,893. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. uniQure has a one year low of $4.72 and a one year high of $21.35.
uniQure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.